Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine

被引：0
|
作者：
Santini, Valeria [1 ]
Amato, Cristina [1 ]
De Pourcq, Sven [2 ]
della Seta, Roberta [3 ]
Caciagli, Barbara [1 ]
Raddi, Marco Gabriele [1 ]
Consagra, Angela [1 ]
Rigodanza, Luca [1 ]
Mattiuz, Giorgio [2 ]
Defina, Marzia [4 ]
Galimberti, Sara [5 ]
Maestrini, Giacomo [6 ]
Sanna, Alessandro [7 ]
机构：
[1] Univ Florence, MDS Unit, DMSC, AOU Careggi, Florence, Italy
[2] Univ Florence, MDS Unit, DMSC, Florence, Italy
[3] Azienda Osped Toscana Nord Ovest, Hematol, Massa Carrara, Italy
[4] Azienda Osped Univ Senese, Hematol, Siena, Italy
[5] Univ Pisa, Dept Clin & Expt Med, Hematol, Pisa, Italy
[6] AOU Toscana Ctr, Hematol, Florence, Italy
[7] AOU Careggi, Hematol, Florence, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190016
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Treatment with Oral Azacitidine in Elderly Patients with Higher Risk Myelodysplastic Syndromes after Response to Subcutaneous Azacitidine
    Santini, Valeria
    Amato, Cristina
    Caciagli, Barbara
    Consagra, Angela
    Rigodanza, Luca
    de Pourcq, Sven
    Cassari, Margherita
    Tofacchi, Elena
    Mattiuz, Giorgio
    Raddi, Marco Gabriele Gabriele
    Sanna, Alessandro
    BLOOD, 2022, 140 : 12313 - 12314
  • [2] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    Dinmohamed, A. G.
    van Norden, Y.
    van de Loosdrecht, A. A.
    Jongen-Lavrencic, M.
    LEUKEMIA, 2016, 30 (08) : 1795 - +
  • [3] Effectiveness of azacitidine in higher-risk myelodysplastic syndromes
    A G Dinmohamed
    Y van Norden
    A A van de Loosdrecht
    M Jongen-Lavrencic
    Leukemia, 2016, 30 : 1795 - 1796
  • [4] The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
    Silverman, L. R.
    Fenaux, P.
    Mufti, G. J.
    Santini, V.
    Hellstrom-Lindberg, E.
    Gattermann, N.
    Sanz, G.
    List, A. F.
    Gore, S. D.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    ECANCERMEDICALSCIENCE, 2008, 2
  • [5] Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes
    Musto, Pellegrino
    Maurillo, Luca
    Spagnoli, Alessandra
    Gozzini, Antonella
    Rivellini, Flavia
    Lunghi, Monia
    Villani, Oreste
    Aloe-Spiriti, Maria Antonietta
    Venditti, Adriano
    Santini, Valeria
    CANCER, 2010, 116 (06) : 1485 - 1494
  • [6] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
  • [7] EFFICACY OF CC-486 (ORAL AZACITIDINE) TREATMENT (TX) IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
    Garcia-Manero, G.
    Savona, M. R.
    Gore, S. D.
    Conkling, P.
    Cogle, C. R.
    Hetzer, J.
    Dong, Q.
    Kumar, K.
    Ukrainskyj, S. M.
    Beach, C.
    Skikne, B. S.
    HAEMATOLOGICA, 2015, 100 : 239 - 239
  • [8] Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes
    Levy, A. R.
    Zou, D.
    Risebrough, N.
    Buckstein, R.
    Kim, T.
    Brereton, N.
    CURRENT ONCOLOGY, 2014, 21 (01) : E29 - E40
  • [9] Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
    Seymour, John F.
    Fenaux, Pierre
    Silverman, Lewis R.
    Mufti, Ghulam J.
    Hellstrom-Lindberg, Eva
    Santini, Valeria
    List, Alan F.
    Gore, Steven D.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 76 (03) : 218 - 227
  • [10] Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes
    Navada, Shyamala C.
    Silverman, Lewis R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (01) : 21 - 27
12345